791 related articles for article (PubMed ID: 21199521)
41. Terlipressin Improves Renal Function and Reverses Hepatorenal Syndrome in Patients With Systemic Inflammatory Response Syndrome.
Wong F; Pappas SC; Boyer TD; Sanyal AJ; Bajaj JS; Escalante S; Jamil K;
Clin Gastroenterol Hepatol; 2017 Feb; 15(2):266-272.e1. PubMed ID: 27464593
[TBL] [Abstract][Full Text] [Related]
42. Hepatorenal syndrome and novel advances in its management.
Fabrizi F; Aghemo A; Messa P
Kidney Blood Press Res; 2013; 37(6):588-601. PubMed ID: 24356549
[TBL] [Abstract][Full Text] [Related]
43. Results of pretransplant treatment of hepatorenal syndrome with terlipressin.
Solà E; Cárdenas A; Ginès P
Curr Opin Organ Transplant; 2013 Jun; 18(3):265-70. PubMed ID: 23652609
[TBL] [Abstract][Full Text] [Related]
44. [Hepatorenal syndrome].
Mijac D; Kezić A; Stojimirović B
Srp Arh Celok Lek; 2007; 135(1-2):98-104. PubMed ID: 17503577
[TBL] [Abstract][Full Text] [Related]
45. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome.
Uriz J; Ginès P; Cárdenas A; Sort P; Jiménez W; Salmerón JM; Bataller R; Mas A; Navasa M; Arroyo V; Rodés J
J Hepatol; 2000 Jul; 33(1):43-8. PubMed ID: 10905585
[TBL] [Abstract][Full Text] [Related]
46. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial.
Solanki P; Chawla A; Garg R; Gupta R; Jain M; Sarin SK
J Gastroenterol Hepatol; 2003 Feb; 18(2):152-6. PubMed ID: 12542598
[TBL] [Abstract][Full Text] [Related]
47. Hepatorenal syndrome.
Guevara M; Ginès P
Dig Dis; 2005; 23(1):47-55. PubMed ID: 15920325
[TBL] [Abstract][Full Text] [Related]
48. Hepatorenal syndrome in patients with cirrhosis.
Moreau R
J Gastroenterol Hepatol; 2002 Jul; 17(7):739-47. PubMed ID: 12121502
[TBL] [Abstract][Full Text] [Related]
49. Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome.
Nazar A; Pereira GH; Guevara M; Martín-Llahi M; Pepin MN; Marinelli M; Solá E; Baccaro ME; Terra C; Arroyo V; Ginès P
Hepatology; 2010 Jan; 51(1):219-26. PubMed ID: 19877168
[TBL] [Abstract][Full Text] [Related]
50. Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies.
Sanyal AJ; Boyer TD; Frederick RT; Wong F; Rossaro L; Araya V; Vargas HE; Reddy KR; Pappas SC; Teuber P; Escalante S; Jamil K
Aliment Pharmacol Ther; 2017 Jun; 45(11):1390-1402. PubMed ID: 28370090
[TBL] [Abstract][Full Text] [Related]
51. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine.
Gülberg V; Bilzer M; Gerbes AL
Hepatology; 1999 Oct; 30(4):870-5. PubMed ID: 10498636
[TBL] [Abstract][Full Text] [Related]
52. New treatments of hepatorenal syndrome.
Arroyo V; Terra C; Ginès P
Semin Liver Dis; 2006 Aug; 26(3):254-64. PubMed ID: 16850375
[TBL] [Abstract][Full Text] [Related]
53. Hepatorenal syndrome.
Guevara M; Rodés J
Int J Biochem Cell Biol; 2005 Jan; 37(1):22-6. PubMed ID: 15381144
[TBL] [Abstract][Full Text] [Related]
54. Long-term treatment of hepatorenal syndrome as a bridge to liver transplantation.
Caraceni P; Santi L; Mirici F; Montanari G; Bevilacqua V; Pinna AD; Bernardi M
Dig Liver Dis; 2011 Mar; 43(3):242-5. PubMed ID: 20833118
[TBL] [Abstract][Full Text] [Related]
55. Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1.
Boyer TD; Sanyal AJ; Garcia-Tsao G; Regenstein F; Rossaro L; Appenrodt B; Gülberg V; Sigal S; Bexon AS; Teuber P;
Liver Transpl; 2011 Nov; 17(11):1328-32. PubMed ID: 21837734
[TBL] [Abstract][Full Text] [Related]
56. Terlipressin versus albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized study.
Singh V; Kumar R; Nain CK; Singh B; Sharma AK
J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 2):303-7. PubMed ID: 16460491
[TBL] [Abstract][Full Text] [Related]
57. Targeting circulatory dysfunction in cirrhosis: terlipressin and the hepatorenal syndrome.
Testro AG; Angus PW
J Gastroenterol Hepatol; 2009 Nov; 24(11):1707-9. PubMed ID: 20136956
[No Abstract] [Full Text] [Related]
58. Meta-analysis: terlipressin therapy for the hepatorenal syndrome.
Fabrizi F; Dixit V; Martin P
Aliment Pharmacol Ther; 2006 Sep; 24(6):935-44. PubMed ID: 16948805
[TBL] [Abstract][Full Text] [Related]
59. Review article: pathogenesis and pathophysiology of hepatorenal syndrome--is there scope for prevention?
Møller S; Henriksen JH
Aliment Pharmacol Ther; 2004 Sep; 20 Suppl 3():31-41; discussion 42-3. PubMed ID: 15335398
[TBL] [Abstract][Full Text] [Related]
60. Hepatorenal syndrome: a severe, but treatable, cause of kidney failure in cirrhosis.
Fagundes C; Ginès P
Am J Kidney Dis; 2012 Jun; 59(6):874-85. PubMed ID: 22480795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
